FDA warned PekCura Labs that its GLP-1-S, GLP-2-T, GLP-3-R, and bacteriostatic water products are unapproved new drugs sold online.
What happened
FDA reviewed PekCura Labs' website in January 2026 and found it offered GLP-1-S, GLP-2-T, GLP-3-R, a Cag/Tirz blend, and Bacteriostatic Water for sale in the United States. The site's labeling included claims about weight loss, blood sugar, cardiovascular outcomes, and metabolic effects, which FDA said showed the products were intended for human use as drugs despite 'Research use only' and 'Not for Human consumption' statements; FDA also said no approved drug applications were in effect.
What FDA found
The products are unapproved new drugs because no FDA-approved application is in effect for them, and selling them across state lines violates the law.
FD&C Act §§301(d), 505(a); 21 U.S.C. §§331(d), 355(a)Website labeling shows the products are intended to treat or affect the body, such as for weight loss, diabetes, and cardiovascular outcomes, so they are drugs despite research-use disclaimers.
FD&C Act §201(g)(1); 21 CFR 201.128The products are new drugs because they are not generally recognized as safe and effective for the uses described in their labeling.
FD&C Act §201(p); 21 U.S.C. §321(p)Bacteriostatic Water is sold with injectable peptides that need reconstitution, which FDA says shows it is intended for injection and is therefore a drug.
FD&C Act §201(g)(1); 21 U.S.C. §321(g)(1)
What FDA wants
FDA asks PekCura Labs to notify it in writing within 15 working days of the specific steps taken to correct the violations, including documentation, and to send the response to FDAAdvisory@fda.hhs.gov with the firm name and identifier 721709. If correction cannot be completed in that time, the company must state the reason and when it will be completed.
Who should pay attention
- online sellers of peptide or GLP-1-like products
- companies marketing injectables as research-use-only
- suppliers and buyers of bacteriostatic water
This is a summary. Read the original letter on fda.gov.